Sisram MedicalSRAMF 60 Days Payable is 48.14 as of Dec. 2025, which is 28% above its 10-year median of 37.59. GuruFocus rates SRAMF with a GF Score™ of 60/100 and a GF Value™ of $0.95 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Sisram Medical ranks worse than 69.06% on this metric.
The historical rank and industry rank for Sisram Medical's Days Payable or its related term are showing as below:
SRAMF'
s Days Payable Range Over the Past 10 Years
Min: 27.8 Med: 37.59 Max: 54.7
Current: 46.71
During the past 12 years, Sisram Medical's highest Days Payable was 54.70. The lowest was 27.80. And the median was 37.59.
SRAMF's Days Payable is ranked worse than 69.06% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 67.87
vs SRAMF: 46.71
Sisram Medical's Days Payable
increased
from Dec. 2024 (40.29) to Dec. 2025 (48.14).
It may suggest that Sisram Medicaldelayed paying its suppliers.
Sisram Medical Days Payable Related Terms
Sisram Medical Days Payable Historical Data
* Premium members only.
The historical data trend for Sisram Medical's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Sisram Medical's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sisram Medical Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sisram Medical's Days Payable distribution charts can be found below:
* The bar in red indicates where Sisram Medical's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Sisram Medical's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sisram Medical (SRAMF) has a Days Payable of 48.14 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sisram Medical and its competitors. This is 28% above median its historical median of 37.59. Over the past decade, Sisram Medical's Days Payable has ranged from 27.80 to 54.70. According to the industry distribution chart, Sisram Medical ranks #549 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 69.1%.
Is Sisram Medical's Days Payable too high?
Sisram Medical's current Days Payable of 48.14 is 28% above median its 10-year median of 37.59. Over the past 10 years, this metric has ranged from a low of 27.80 to a high of 54.70. The Medical Devices & Instruments industry median Days Payable is 67.87. Sisram Medical's value of 48.14 is 29.1% below this industry median. Based on the distribution chart, Sisram Medical ranks #549 out of 795 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Sisram Medical has a GF Score™ of 60/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sisram Medical's Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Sisram Medical ranks #549 out of 795 companies for Days Payable. This places Sisram Medical in the lower half of its industry. The industry median Days Payable is 67.87. Sisram Medical's value of 48.14 is 29.1% below this benchmark. Historically, Sisram Medical's own Days Payable has ranged from 27.80 to 54.70 over the past decade. While the company's 10-year median is 37.59 vs. the industry median of 67.87, Sisram Medical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.87, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sisram Medical's current Days Payable of 48.14 is 29.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sisram Medical and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sisram Medical's current Days Payable is 48.14, which is 28% above median its own 10-year median of 37.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sisram Medical stock overvalued right now?
Based on GuruFocus' analysis, Sisram Medical (SRAMF) is currently considered Significantly Undervalued. The stock's GF Value™ is $0.95, compared to a current price of $0.44 — trading 53.9% below its estimated fair value. The current Days Payable is 48.14, which is 28% above median its 10-year median of 37.59 and 29.1% below the Medical Devices & Instruments industry median of 67.87. Sisram Medical's overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Sisram Medical (SRAMF), the current Days Payable is 48.14 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sisram Medical (SRAMF) Overvalued in 2026?
Based on GuruFocus' analysis, Sisram Medical stock appears to be undervalued.
The current stock price of $0.44 is trading 53.9% below its estimated GF Value™ of $0.95.
GuruFocus considers Sisram Medical to be Significantly Undervalued.
Key valuation signals for SRAMF:
Days Payable: 48.14 (28% above median its 10-year median of 37.59)
GF Value™: $0.95 vs. price of $0.44 (53.9% below fair value)
Industry Position: 29.1% below the Medical Devices & Instruments median (#549 of 795)
No single metric tells the full story. See the SRAMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sisram Medical Ltd is an investment holding company specializing in medical technology for healthcare. The Company is involved in research, development, design, manufacture, sale and marketing of medical aesthetics and dental equipment, home use devices, injectables and cosmeceuticals products. The company's products include Soprano Titanium, Colibri technology, and others. Some of the company's brands are Alma, Soprano, Copulla, and LMNT. It operates through the following geographical segments: North America which is its key revenue generating market, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
60GF Score
Get the complete analysis for SRAMF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SRAMF has been successfully added to your 
